To evaluate the expression levels of the endocannabinoid receptors CB2 (Cnr2) and GPR55 (Gpr55) during the course of AD pathology, we have evaluated and compared their hippocampal gene expression in wild-type (WT) and the AppNL-G-F mice at 3, 6, and 12 months of age. This evidence concerns the gene CNR2 and Alzheimer disease.